Fresh analysis indicates that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who halt conventional lifestyle programs.
Findings released in a major health publication points out that while overweight individuals often shed a large proportion of their body weight while using the jabs, the mass comes back at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing such drugs need to be informed of the risk of quick rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
That rate of recovery means a return to starting weight in about 18 months.
Analyzing Approaches
The study, which examined 37 of trials involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
The team note that people who shed pounds through diet and exercise generally see a more gradual weight regain—around 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Nutrition scientists propose the mechanism of the injections explains the heightened rebound.
The injections mimic a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels far above than normal may cause the body to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' results in appetite is uncontrolled, making overeating much more probable."
An Ongoing Disease?
Medical guidelines recommend the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Professionals argue that, considering the likelihood of weight regain, the treatment should be considered long-term.
This perspective is supported by drug manufacturers, who state that the findings "emphasize the long-term nature of excess weight," comparing it to managing diseases like hypertension.
Patient Accounts
People who have come off the medication describe a powerful return of hunger.
"It felt as if a switch activating and I was suddenly starving," said one woman.
This challenge is exacerbated if patients have not developed lasting dietary or behavioural changes during therapy.
Growing Adoption
Survey data show that a significant number of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Use is more common among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, experts caution that while the jabs are potent agents for shedding pounds, they are not a permanent cure and lasting health benefits relies on integrated behavioural changes.
